Richard Sater is a Neurology physician affiliated with Cone Health. OpenAlex indexes 15 publications with 485 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
912 3rd St Ste 101
Greensboro, NC 27405
Telephone
336-273-2511Provider last certified this registry record 20 Sept 2021.
Clinical trials
- NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
Sponsor: Cornerstone Health Care, PA
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
69 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year202531 payments$41,193openpaymentsdata.cms.gov ↗
- TG Therapeutics, Inc.Program year202533 payments$20,218openpaymentsdata.cms.gov ↗
- Biogen, Inc.Program year202519 payments$11,815openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
70.3%Gabapentinoids13.2%Gabapentin79%Pregabalin20%Horizant2%Part D<11 patientsBenzodiazepine8.1%Clonazepam40%Diazepam25%Lorazepam21%Alprazolam14%Part D≥36 patients+ 30 more classes in this area
Musculoskeletal
12.2%gamma-Aminobutyric Acid-ergic Agonist6.2%Baclofen100%Part D≥95 patientsCentral alpha-2 Adrenergic Agonist2.6%Tizanidine Hcl100%Part D≥39 patients+ 2 more classes in this area
Cancer & immunology
7.2%Pyrimidine Synthesis Inhibitor2.8%Teriflunomide81%Aubagio19%Part D<11 patientsOther immunosuppressants1.2%Dimethyl Fumarate100%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Thomas Stuckey, MD
Cone Health
Daniel Bensimhon, MD
Cone Health
Murali Ramaswamy, MD, FAAFP
Cone Health
Vinay Gudena, MD
Cone Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”